Related Experiment Video
Updated: Jun 18, 2026
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a
S I Nihtyanova1, E C Tang, J G Coghlan
1Centre for Rheumatology, Royal Free Hospital, London NW3 2QG, UK.
Insights
Improved survival in systemic sclerosis (SSc) is linked to better detection of lung complications. Early screening for diffuse cutaneous SSc (dcSSc) significantly enhances outcomes.
Area of Science:
- Rheumatology
- Pulmonology
- Clinical Epidemiology
Background:
- Systemic sclerosis (SSc) is a severe autoimmune disease with high mortality and morbidity.
- Current management emphasizes early detection and treatment of organ-specific complications.
- Understanding trends in complication ascertainment and their impact on survival is crucial.
Purpose of the Study:
- To investigate changes in the detection of major organ complications in Systemic Sclerosis (SSc) over time.
- To determine if improved ascertainment of complications is associated with enhanced patient survival.
- To compare outcomes between historical and contemporary SSc cohorts.
Main Methods:
- Retrospective cohort analysis of 520 Systemic Sclerosis (SSc) patients.
- Comparison of patients with disease onset between 1990-1993 (historical) and 2000-2003 (contemporary).
- Analysis of survival rates and the frequency of internal organ complications between the two cohorts.
Main Results:
- Five-year survival improved significantly for diffuse cutaneous SSc (dcSSc) patients from 69% to 84% (P=0.018).
- Clinically significant pulmonary fibrosis and pulmonary arterial hypertension diagnoses increased markedly in the contemporary cohort for both limited cutaneous SSc (lcSSc) and dcSSc.
- No significant survival differences were observed for scleroderma renal crisis or cardiac involvement.
Conclusions:
- Survival has substantially improved for the diffuse cutaneous subset of Systemic Sclerosis (SSc).
- Enhanced and more complete ascertainment of lung complications, driven by systematic annual screening, is associated with improved survival.
- These findings underscore the importance of proactive screening for pulmonary manifestations in dcSSc.
Background:
Systemic sclerosis (SSc) has high mortality and morbidity. Current management focuses on early detection and treatment of organ-based manifestations.
Aim:
To determine whether the ascertainment of major organ complications of SSc has changed over time and if this is associated with better survival.
Design:
Retrospective cohort analysis.
Methods:
A total of 520 SSc patients, 234 with disease onset between 1990 and 1993 (historical cohort) and 286 with disease onset between 2000 and 2003 (contemporary cohort), were included. Survival and frequency of internal organ complications were compared between the two cohorts.
Results:
Five-year survival among diffuse cutaneous SSc (dcSSc) patients has improved from 69% in the 1990-93 cohort to 84% in the 2000-03 cohort (P = 0.018), whereas 5-year survival among the limited cutaneous SSc (lcSSc) patients has remained unchanged-93 and 91%, respectively. Sixteen per cent of the lcSSc subjects and 38% of the dcSSc subjects from the contemporary cohort were diagnosed for the clinically significant pulmonary fibrosis compared with 3 and 7%, respectively, of the historical cohort (P < 0.001). Similarly, the diagnosis of pulmonary arterial hypertension was more frequent in the patients from the contemporary cohort (8 and 7% for lcSSc and dcSSc, respectively) compared with [ < 1% (P = 0.002) and 1% (P = 0.148), respectively] the historical cohort. There was no significant difference between the two cohorts in terms of scleroderma renal crisis and cardiac involvement.
Conclusion:
Survival has substantially improved for the diffuse cutaneous subset of SSc with better and more complete ascertainment of lung complications as a result of systematic annual screening.